Industry and regulatory performance in 2012: A year in review

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 359-366

  Dowden, H M ^a   Jahn, R ^a   Catka, T ^a   Jonsson, A ^a   Michael, E ^a   Miwa, Y ^a   Zinkand, W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALOGLIPTIN; ALZHEIMER DISEASE VACCINE; AMFEBUTAMONE PLUS NALTREXONE; APIXABAN; BAPINEUZUMAB; BEDAQUILINE; BOCEPREVIR; CROFELEMER; DABIGATRAN ETEXILATE; DALCETRAPIB; DAPAGLIFLOZIN; DOCETAXEL; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; IVACAFTOR; LORCASERIN; LUMACAFTOR; PERTUZUMAB; PHENTERMINE PLUS TOPIRAMATE; RAXIBACUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIVAROXABAN; SOLANEZUMAB; TELAPREVIR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VISMODEGIB; WARFARIN;

ALZHEIMER DISEASE; ANTHRAX; BASAL CELL CARCINOMA; BLEEDING; BRAZIL; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHINA; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; EMBOLISM; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; JAPAN; METASTASIS; MEXICO; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RUSSIAN FEDERATION; SKIN CANCER; TUBERCULOSIS; UNITED STATES; DRUG DEVELOPMENT; ECONOMICS; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; RESEARCH; RISK ASSESSMENT; TRENDS;

DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; GOVERNMENT REGULATION; RESEARCH; RISK ASSESSMENT;

EID: 84883137462     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.91     Document Type: Review

References (37)

1. Jenkins, J.K. CDER new drug review: 2012 update, slide 13. FDA/CMS Summit, 10 December 2012.
2. McCaughan, M. FDA's very big year. RPM Report, 2 January 2013.
3. Jenkins, J.K. CDER new drug review: 2012 update, slides 18-19. FDA/CMS Summit, 10 December 2012.
4. Jenkins, J.K. CDER new drug review: 2012 update, slides 5-6. FDA/CMS Summit, 10 December 2012.
5. Genzyme. Genzyme provides update on U.S. LEMTRADA™ Filing. Company press release, 27 August 2012.
6. Jenkins, J.K. CDER new drug review: 2012 update, slide 10. FDA/CMS Summit, 10 December 2012.
7. Jenkins, J.K. CDER new drug review: 2012 update, slide 10. FDA/CMS Summit, 10 December 2012.
8. Centre for Innovation in Regulatory Science (CIRS). New drug approvals in ICH countries: 2002-2011. Prepared by Tina Wang, Research Analyst, CIRS, and Neil McAuslane, Scientific director, 2012.
9. Procedures for marketing authorization. Chapter 6: decision making procedure for the adoption of commission decisions. European Commission, November 2005. .
10. International Regulatory Harmonization. WHO Drug Info. 26(4), (2012). .
11. Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867-882 (2010).
12. EvaluatePharma World Preview 2018, June 2012. http://www.evaluategroup. com/Public/Reports/Evaluate-World-Preview-2013-Outlook-to-2018.aspx.
13. Economist Conference 2012. Welcome to the mini-buster. EP Vantage, 29 November 2012.
14. Vertex. FDA approves KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis. Company press release, 31 January 2012.
15. Chase, B. Vertex announces pivotal trial for cystic fibrosis therapy. SCRIP Intelligence, 27 February 2013.
16. Palmer, E. EU OKs Vertex cystic fibrosis drug Kalydeco. FiercePharma, 27 July 2012.
17. EvaluatePharma Kalydeco Worldwide Archived Forecast, 20 May 2012.
18. Vertex slides as Kalydeco numbers fail to add up. EP Vantage, 5 November 2012.
19. EvaluatePharma Worldwide Forecasts, 7 January 2013.
20. Roche. FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma. Company press release, 30 January 2012.
21. Top Ten Oncology Approvals in 2012 Add $5.2b to the Market by 2018. Decision Resources, 24 December 2012.
22. Hayes, E. Kadcyla positioned for wide use in metastatic breast cancer. Pink Sheet Daily, 22 February 2013.
23. Spotlight On: FDA approvals to date in 2012. FirstWord Pharma, 10 July 2012.
24. NDA 022580 Approval Letter to Vivus Inc. http://www.accessdata.fda.gov/ drugsat.fda-docs/appletter/2012/022580Origs000ltr.pdf
25. Pfizer. ELIQUIS? (apixaban), Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation. Company press release, 20 November 2012.
26. CDC to recommend HCV testing of all baby boomers. BioCentury Extra, 18 May 2012.
27. Hansen, S. HCV doctors: anemia, payer preference add to sales decline for Vertex's Incivek. BioCentury, 12 November 2012.
28. FDA adds boxed warning to Incivek label. BioCentury Extra, 19 December 2012.
29. Davis, J. Novo Nordisk dismayed by "complete response" letter for insulin degludec. The Pink Sheet Daily, 11 February 2013.
30. Measuring the return from pharmaceutical innovation 2012. Deloitte Centre for Health Solutions.
31. Approvals up, revenues down, but R&D productivity on mend. BioWorld International, 5 December 2012.
32. Sadeghi-Nejad, N. The lessons of failure: what we can learn from bapineuzumab's blowup. Forbes, 7 August 2012.
33. Martin, B. Elan's AN1792: no clinical benefit with clearance of amyloid plaques in AD. Pathophilia, 21 July 2009.
34. Lilly plans trial for solanezumab. Yahoo Finance, 13 December 2012.
35. Husten, L. Roche terminates development of CETP inhibitor dalcetrapib. Forbes, 7 May 2012.
36. Voight, B.F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).
37. Merck & Co. Merck provides update on next steps for TREDAPTIVETM extended-release niacin/laropiprant. Company press release, 11 January 2013.